Apoptosis and chemotherapy resistance

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 921-926

  Hickman, J A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; IRINOTECAN; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53; THYMIDYLATE SYNTHASE; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; DNA DAMAGE; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0029941463     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00080-9     Document Type: Article

References (67)

1. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994, 76, 777-779.
2. Wyllie AH. Cell death: a new classification separating apoptosis from necrosis. In Bowen ID, Lockshin RA, eds. Cell Death in Biology and Pathology. London, Chapman and Hall, 1981.
3. Raff MC. Social controls on cell survival and cell death. Nature 1993, 356, 397-400.
4. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 1994, 77, 477-478.
5. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124, 619-626.
6. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
7. Pullan S, Wilson J, Metcalfe A, et al. Requirement of basement membrane for suppression of programmed cell death in mammary epithelium. J Cell Sci 1996, 109, 631-642.
8. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Genet Dev 1994, 4, 120-129.
9. Nagata S. Apoptosis regulated by a death factor and its receptor: fas ligand and fas. Phil Trans R Soc Lond (B) 1994, 345, 281-287.
10. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335, 440-442.
11. Hockenbery D, Nuňez G, Milliman C, Schrieber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-336.
12. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994, 124, 1-6.
13. Yin X-M, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369, 321-323.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993, 74, 609-619.
15. Núñez G, Merino R, Grillot D, González-García M. Bcl-2 and Bcl-x: regulator switches for lymphoid death and survival. Immunology 1994, 12, 582-588.
16. 1 and bcl-2, displaces bax and promotes cell death. Cell 1995, 80, 285-291.
17. Kiefer MC, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995, 374, 736-739.
18. Farrow SN, White JHM, Martinou I, et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374, 731-733.
19. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995, 374, 733-736.
20. Sato T, Hanada M, Bodrug S, et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994, 91, 9238-9242.
21. Merritt AJ, Potten CS, Watson AJM, et al. Differential expression of bcl-2 in intestinal epithelia. J Cell Sci 1995, 108, 2261-2271.
22. Clurman BE, Roberts JM. Cell cycle and cancer. J Natl Cancer Inst 1995, 87, 1499-1501.
23. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 1991, 64, 192-196.
24. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78, 539-542.
25. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992, 11, 121-139.
26. Dive C, Wyllie AH. Apoptosis and cancer chemotherapy. In Hickman JA, Tritton TR, eds. Cancer Chemotherapy. Oxford, Blackwell, 1993, 21-56.
27. Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. In Dexter TM, Raff MC, Wyllie AH, eds. The Role of Apoptosis in Development, Tissue Homeostasis and Malignancy. London, Chapman and Hall, 1994, 83-89.
28. Kerr JFR, Searle AJ, Harmon BV, Bishop CJ. In Potten CS, ed. Perspectives on Mammalian Cell Death. Oxford Science Publications, Oxford, 1987, 93-128.
29. Ijiri K, Potten CS. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983, 47, 175-185.
30. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JFR. An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975, 116, 129-138.
31. Yin DX, Schimke RT. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 1995, 55, 4922-4928.
32. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 79, 329-339.
33. L by cytotoxic drug exposure confers resistance to ionising radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 1995, 6, 363-370.
34. L and bcl-2 repress a common pathway of cell death. J Exp Med 1995, 182, 821-828.
35. Gottschalk AR, Boise LH, Thompson CB, Quitáns J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA 1994, 91, 7350-7354.
36. S sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995, 55, 2507-2510.
37. Levi-Montalcini R. The nerve growth factor: thirty-five years later. EMBO J 1987, 6, 1145-1154.
38. Harrington EA, Bennett MR, Fanidi A, Evan GI. C-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994, 13, 3286-3295.
39. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990, 343, 76-82.
40. Chapman RS, Whetton AD, Dive C. The suppression of drug-induced apoptosis by activation of v-abl protein tyrosine kinase. Cancer Res 1994, 54, 5131-5137.
41. Evans CA, Lord JM, Owen-Lynch PJ, Johnson C, Dive C, Whetton AD. Suppression of apoptosis by v-Abl protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haematopoietic cell line. J Cell Sci 1995, 108, 2591-2598.
42. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spandidos DA. Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 1987, 56, 251-259.
43. Nooter K, Boersma AWM, Oostrum RG, Burger H, Jochemsen AG, Stoter G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 1995, 71, 556-561.
44. Lane DP. p53, guardian of the genome. Nature 1993, 358, 15-16.
45. Bayle JH, Elenbaas B, Levine AJ. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci USA 1995, 92, 5729-5733.
46. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Aciad Sci USA 1992, 89, 7491-7495.
47. El-Diery WS, Tokino T, Veculesco VE, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817-825.
48. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992, 52, 5407-5411.
49. Clarke AR, Purdi CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362, 849-852.
50. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362, 847-853.
51. Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-induced apoptosis in gastrointestinal tract of normal and p53-dependent mice. Cancer Res 1994, 54, 614-617.
52. Lowe SW, Bodis S, McClatchey LR, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266, 807-810.
53. Slickenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993, 53, 4164-4168.
54. Fan S, Smith ML, Rivett DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55, 1649-1654.
55. Evans DL, Tilby M, Dive C. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 1994, 54, 1596-1603.
56. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995, 376, 596-599.
57. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human bcl-2 modulates nitrogen mustard and campthothecin induced apoptosis. Cancer Res 1993, 53, 1853-1861.
58. Kondo S, Yin D, Takeuchi J, Morimura T, Oda Y, Kikuchi H. bcl-2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy. Br J Cancer 1994, 70, 421-426.
59. Collins MKL, Marvel J, Malde P, Lopez-Rivas A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 1992, 176, 1043-1051.
60. Dole M, Nuñez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994, 54, 3253-3259.
61. Kondo S, Yin D, Morimura T, Takeuichi J. bcl-2 gene prevents induction of apoptosis in L1210 murine leukemia cells by SN-38, a metabolite of the campthothecin derivative CPT-11. Int J Oncol 1994, 4, 649-654.
62. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizaw A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993, 53, 4251-4256.
63. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation - competent and defective myeloid leukemic cells. Cell Growth & Diff 1993, 4, 41-47.
64. Fisher TC, Milner AE, Gregory CD, et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993, 53, 3321-3326.
65. Gao X, Kundsen TB, Ibrahim MM, Haldar S. Bcl-2 relieves deoxyadenylate stress and suppresses apoptosis in pre-B leukemia cells. Death and Differentiation 1995, 2, 69-78.
66. Alnemri ES, Fernandes TF, Haldar S, Croce CM, Litwack G. Involvement of bcl-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer Res 1992, 52, 491-495.
67. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81, 151-157.